Hoechst Pakistan Limited (PSX: HPL)

Market Cap	28.93B
Revenue (ttm)	26.01B
Net Income (ttm)	1.62B
Shares Out	9.64M
EPS (ttm)	167.77
PE Ratio	17.88
Forward PE	n/a
Dividend	50.00 (1.63%)
Ex-Dividend Date	Sep 3, 2024

Volume	410
Average Volume	263
Open	3,000.00
Previous Close	3,066.70
Day's Range	2,960.00 - 3,045.00
52-Week Range	1,210.01 - 3,480.00
Beta	0.25
RSI	60.65
Earnings Date	Apr 16, 2025

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its antibiotic, cardiology, diabetes, pain and allergy, and other products under Flagyl, Clexane, NO-SPA, Lantus, Amaryl, Claforan, Haemaccel, Enterogermina, and Plavix brands. It also offers various shampoos under the Selsun Blue brand name. The company was formerly known as Sanofi-Aventis Pakistan Limited and changed its name to Hoechst Pakistan Limited in September 2...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 734
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HPL

Financial Performance

In 2023, Hoechst Pakistan's revenue was 21.37 billion, an increase of 15.14% compared to the previous year's 18.56 billion. Earnings were 360.81 million, an increase of 116.33%.